Estrogen dominance

What it is

Estrogen dominance is a hormonal state in which estrogen exerts disproportionately high influence on the body relative to progesterone — affecting an estimated 50% of women over 35 in some clinical surveys, though precise Canadian prevalence data remain limited. Also called estrogen-progesterone imbalance or relative hyperestrogenism, the condition does not always mean estrogen levels are abnormally elevated. It can occur when estrogen sits within a technically normal range but progesterone is too low to counterbalance it.

During a healthy menstrual cycle, estrogen dominates the follicular phase (roughly days 1–14), then progesterone rises in the luteal phase after ovulation. When that balance breaks down — through anovulation, progesterone deficiency, excess estrogen from internal or external sources, or impaired estrogen clearance — estrogen dominance can develop. Estrogen dominance is not a formally codified diagnosis in the ICD-11 or DSM-5, but it is a clinically recognized hormonal pattern with measurable markers and identifiable symptoms. Several well-established conditions — including polycystic ovary syndrome (PCOS), perimenopause, and luteal phase deficiency — involve estrogen dominance as a central feature.

Causes and mechanism

Estrogen dominance arises from two broad pathways: too much estrogen, too little progesterone, or both simultaneously.

Causes of relatively elevated estrogen:

Source	Mechanism
Anovulation	No corpus luteum forms, so no progesterone is produced in the luteal phase
Obesity	Adipose tissue expresses aromatase, converting androgens to estrogen peripherally
Perimenopause	Cycles become increasingly anovulatory in the 2–10 years before menopause
Xenoestrogen exposure	Certain plastics (BPA), pesticides, and synthetic fragrances mimic estrogen at receptors
Liver dysfunction	Impaired hepatic clearance allows estrogen to recirculate rather than be excreted

Causes of relatively low progesterone:

• Luteal phase deficiency: insufficient progesterone output after ovulation, often confirmed by a mid-luteal serum progesterone below 9.5 nmol/L on the Canadian reference range.
• Chronic stress: cortisol and progesterone share the precursor pregnenolone. Under sustained stress, the body preferentially channels pregnenolone toward cortisol, reducing progesterone synthesis.
• Thyroid dysfunction: hypothyroidism impairs both progesterone production and hepatic estrogen metabolism, compounding the imbalance.
• PCOS: anovulatory cycles mean progesterone is rarely produced in the second half of the cycle.

Symptoms and diagnosis

Symptoms reflect prolonged, unbalanced estrogen stimulation of estrogen-sensitive tissues:

• Irregular, heavy, or prolonged menstrual bleeding
• Breast tenderness or swelling, especially premenstrually
• Bloating and fluid retention
• Mood changes: irritability, anxiety, premenstrual dysphoric disorder (PMDD)
• Weight gain around the hips, thighs, and lower abdomen
• Fatigue and difficulty sleeping
• Premenstrual headaches
• Low libido
• In some cases, uterine fibroids or endometrial hyperplasia

Diagnostic evaluation typically includes:

1. Serum estradiol and progesterone — estradiol measured in the follicular phase; progesterone drawn approximately 7 days before the expected period to assess luteal function. Both LifeLabs and Dynacare offer cycle-timed hormone panels across most Canadian provinces.
2. Estrogen-to-progesterone ratio — provides a picture of relative hormonal balance rather than absolute levels alone.
3. Thyroid panel (TSH, free T4) — thyroid dysfunction frequently co-exists and worsens estrogen metabolism.
4. SHBG (sex hormone-binding globulin) — low SHBG increases free estrogen bioavailability even when total estradiol appears normal.
5. Ovulation assessment — via basal body temperature charting, urinary LH kits, or mid-luteal progesterone.

Treatment options

Treatment targets the underlying cause of the imbalance rather than estrogen levels in isolation.

Lifestyle approaches:

• Weight management reduces peripheral aromatase activity; even a 5–10% reduction in body weight can meaningfully lower estrogen production in people with obesity.
• Liver support through reduced alcohol intake, adequate B vitamins, and cruciferous vegetables (which contain diindolylmethane, or DIM, a compound that supports estrogen metabolism pathways).
• Reducing xenoestrogen exposure by choosing glass or stainless steel food containers, filtering drinking water, and minimizing synthetic fragrance products.
• Stress reduction to protect progesterone levels by moderating cortisol output.

Medical treatment:

• Oral micronized progesterone (e.g., Prometrium) — used in the luteal phase to counterbalance estrogen; available by prescription in Canada and covered under many provincial drug benefit plans.
• Levonorgestrel-releasing IUD (Mirena) — reduces endometrial stimulation from estrogen and controls heavy bleeding; covered under most provincial plans with a prescription.
• Ovulation induction — where fertility is desired and anovulation is the root cause.
• Treating underlying conditions — resolving hypothyroidism, managing PCOS, or addressing liver dysfunction directly corrects the hormonal environment.

Canadian patients can access hormonal assessments and prescriptions through their family physician, a gynaecologist, or virtual care platforms (Felix, Maple, Cleo, Phoenix, and others) that serve most provinces.

When to see a clinician in Canada

Seek assessment if you experience heavy or irregular periods, significant premenstrual symptoms that interfere with daily functioning, unexplained breast tenderness that tracks with your cycle, or concerns about fibroids or endometrial health. A cycle-timed hormonal panel — estradiol, progesterone, TSH, and SHBG — ordered through your primary care provider or a virtual care service is a reasonable starting point. The Society of Obstetricians and Gynaecologists of Canada (SOGC) recommends that abnormal uterine bleeding, a common presentation of estrogen dominance, be investigated promptly to rule out endometrial pathology.

Limitations and open questions

Research is still emerging on several aspects of estrogen dominance. The estrogen-to-progesterone ratio lacks a universally agreed clinical threshold; reference ranges vary between laboratories and guidelines, and no single cut-off has been validated in large prospective Canadian cohorts. The role of environmental xenoestrogens in driving clinically significant hormonal imbalance in humans — as opposed to animal models — remains debated in the peer-reviewed literature. Evidence on topical progesterone cream (as opposed to oral micronized progesterone) is mixed: transdermal absorption is variable and serum levels achieved are generally lower than with oral formulations. Health Canada has not issued specific guidance on DIM supplements or phytoestrogen supplements for estrogen dominance management, and the evidence base for these interventions in humans is limited. Clinicians and patients should weigh lifestyle and supplement recommendations against this uncertainty.